Skip to content

Sareum Holdings: CEO Tim Mitchell talks about his COVID research pipeline

*

Early-stage pharma developer Sareum Holdings (AIM:SAR) is making good progress on its pipeline of projects, justifying the share price rise increases earlier this year.

With Covid spreading damage particularly hard in the UK in the early months of 2021 shares rocketed to 8.85 pence in August – from 220 pence at the end of 2020 – as investors' focus zeroed in on the company’s research on a molecule that could be used to treat breathing complications caused by the virus.


Want the full story? Access all of The Armchair Trader's content for just £5.99 per month.

Get weekly investment ideas and tips that will take your investing to the next level. Sign up here.

Free 28 day trial. Cancel anytime.


Log In or Sign Up to Armchair Trader+

Already a member? Log in here:


Not a member? Sign up now or see the membership benefits

Further content of this article is not available as it is for members only. Please visit the registration page for Armchair Trader Plus+ for further details on the benefits of becoming a member.

Invest with these platforms

Hargreaves Lansdown IG Interactive Brokers Interactive Investor Charles Stanley
IG Interactive Brokers Charles Stanley

Looking for great investing ideas? Sign up to our free newsletter.

Join our UK news channel on WhatsApp

This article does not constitute investment advice. Make sure you do your own research or consult a professional advisor.

Learn with our free 'How to' Guides

Our latest in-depth company reports

Detailed reviews of selected companies and investment trusts.

On the podcast

Sign up for great investing stock tips

Thanks to our Site Partners

Our partners are established, regulated businesses and we are grateful for their support.

Aquis
CME Group
FP Markets
Pepperstone
Admiral Markets

TMX
WisdomTree
ARK
FxPro
IG
Back To Top